New compound kills cancer cells by starving them of glucose
Washington, Aug 4 : Researchers at the Stanford University School of Medicine have identified a compound called STF-31 that attacks the Achillesa€™ heel of certain cancer cells by depriving them of their energy source, the sugar glucose.
a€oeThis study demonstrates an approach for selectively inhibiting the ability of cancer cells to take up glucose, which is a pretty powerful way of killing those cells,a€ said senior study author Amato Giaccia, PhD, professor and director of radiation oncology.
The researchers focused their study on the most common form of kidney cancer in adults, renal cell carcinomas, which is resistant to typical chemotherapies.
Most renal cell carcinomas produce energy through a biochemical process called aerobic glycolysis, one that healthy cells dona€™t typically require. The energy-making process is dependent on the cellsa€™ ability to take up glucose from their environment.
a€oeThe cells that we are targeting are highly dependent on glucose transport for energy production,a€ said Denise Chan, PhD, former postdoctoral researcher at Stanford and co-first author of the new study.
a€oeThis compound stops the cells from transporting glucose, so it starves them,a€ he added. (Agencies)
No comments yet! Be the first one to leave a comment.
|Washington, April 22: Extending the hope to live longer than expected for patients suffering from brain cancer, a team of scientists has found a molec|
|Washington, Feb 23 : Scientists have identified a potential therapeutic target for brain cancer. They have discovered a protein that is highly expre|
|Washington, September 1 (ANI): Natural compounds present in plants and some vegetables may help treat cancer even more effectively, when used side-by-|
|London, Nov 10 : Early cancer diagnostic may now be possible, as researchers have identified the gene responsible for initiating human cancer.
|London, Sept 30 (IBNS) Scientists have used a brand new technique for examining individual stem cells to uncover dramatic differences in the gene expr|
The Thyroid Epidemiological Study team was led by Dr. A. G Unnikrishnan, Principal Investigator of the study and CEO and Endocrinologist, Chellaram Diabetes Institute, Pune; Dr. Mary D' Cruz, Kolkata Investigator and Consultant Physician, Kolkata; and other researchers.
This study initiated by Abbott is India's first cross-sectional and multi-city study to q ... Read More